Structure Therapeutics (NASDAQ: GPCR) received a significant boost in its price target from JPMorgan Chase & Co., which raised it from $65.00 to $105.00...
Barclays has downgraded shares of Rapt Therapeutics (NASDAQ:RAPT) from an overweight rating to an equal weight rating, according to a research note published on...